From: Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer
Dose-volume measure | At baseline | After MDHeart reduction | After VHeart-50-Gy reduction | After VLAwall-63-Gy reduction |
---|---|---|---|---|
EQD2Lung-mean* | 13.7 Gy (8.0, 16.8 Gy) | 13.9 Gy (7.2, 16.6 Gy) p = 0.03 | 13.7 Gy (7.7, 16.7 Gy) p = 0.07 | 14.1 Gy (8.0, 16.8 Gy) p = 0.86 |
Mean lung dose | 15.7 Gy (9.4, 19.5 Gy) | 15.8 Gy (8.5, 19.3 Gy) p = 0.03 | 15.7 Gy (9.1, 19.4 Gy) p = 0.06 | 16.0 Gy (9.4, 19.5 Gy) p = 0.89 |
VLung-10-Gy** | 47.2% (29.0,70.9%) | 46.3% (27.6, 73.9%) p = 5 × 10–3 | 46.5% (29.0, 76.5%) p = 0.16 | 47.5% (29.0, 77.4%) p = 0.88 |
VLung-20-Gy | 27.2% (15.6, 34.4%) | 28.1% (13.6, 34.8%) p = 0.98 | 26.4% (14.9, 34.5%) p = 0.30 | 26.4% (15.6, 34.9%) p = 0.94 |
VLung-30-Gy | 17.1% (7.9, 23.7%) | 16.4% (6.7, 24.5%) p = 0.59 | 16.7% (7.7, 23.7%) p = 8 × 10–3 | 16.6% (7.9, 23.7%) p = 0.72 |
VLung-50-Gy | 7.0% (2.6, 12.2%) | 6.9% (2.2, 14.4%) p = 1.00 | 7.0% (2.4, 12.6%) p = 0.05 | 7.5% (2.6, 12.2%) p = 0.30 |